Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years old;

• Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy;

• The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy);

• The target lesion of the lung receiving radiotherapy can be measured;

• Imaging data can be obtained before and after radiotherapy;

• Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.

Locations
Other Locations
China
China-Japan Friendship Hospital
RECRUITING
Beijing
Renmin Hospital of Wuhan University
RECRUITING
Wuhan
Contact Information
Primary
Guangying Zhu, M.D.
zryyfa@163.com
+86 010-84205380
Time Frame
Start Date: 2024-12-25
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: China-Japan Friendship Hospital

This content was sourced from clinicaltrials.gov